Clinical Trial Update: Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update for ruxolitinib in treating hypereosinophilic syndrome and other primary eosinophilic disorders; the study is currently in recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilia
• Eosinophilic Leukemia Not Otherwise Specified
• Hypereosinophilic Syndrome

Drugs mentioned

• Jakafi (Ruxolitinib) (Ruxolitinib)

Snippet

Sponsor: William Shomali | Conditions: BCR-JAK2 Fusion Protein Expression, Blasts 20 Percent or Less of Peripheral Blood White Cells | Phase 2 | Status: RECRUITING